Navigation Links
Highmark Presents Work on MRSA Prevention at National Health Care Quality Conference
Date:12/11/2007

QualityBLUE program works with hospitals to help reduce spread of MRSA

PITTSBURGH, Dec. 11 /PRNewswire/ -- At a national forum on quality in health care, Highmark officials presented information on one aspect of their pay-for-performance program designed to deal with Methicillin Resistant Staphylococcus Aureus (MRSA). Highmark's program, called QualityBLUE, has been extremely successful for hospitals in western Pennsylvania in identifying patients that have been infected with the disease.

"By identifying patients who are carriers of MRSA earlier than in the past, hospitals are reducing the spread of the disease and reducing mortality, decreasing length of stay and use of antibiotics, and ultimately having significantly improved outcomes for patients," said Deborah Donovan, director, Provider Quality Performance Management at Highmark. "Highmark is working collaboratively with 30 hospitals in Pennsylvania. It is in great part because of this cooperation that the program has been so successful."

The poster presentation was made today at the 19th Annual National Forum on Quality Improvement for Health Care in Orlando, Fla. and sponsored by the Institute for Healthcare Improvement (IHI). In December 2006, the IHI added the reduction of MRSA infections to its new 5 Million Lives campaign. Participating hospitals submit such data as the percentage of patients who were tested for MRSA on admission and compliance with prevention techniques.

Highmark's pay-for-performance program began targeting MRSA testing and prevention initiatives in July 2005. "We have made it easier for participating hospitals to work with IHI and Highmark," said Donovan.

Results from Highmark's fiscal year 2007 review show that during the past year, 8.4 percent of patients admitted to hospitals' high-risk areas such as the intensive care unit were identified as carriers of MRSA. With the thorough screening program, the spread of MRSA has been reduced. Measures
'/>"/>

SOURCE Highmark Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2008)... WASHINGTON, Oct. 12 /- Bos...ounced results from an analysis,of nearly 7,500 pa...hich,are designed to confirm the performance of th...y Stent System in real-world practice. The,two-yea...educed clinical,restenosis in patients with diabet...
(Date:10/10/2008)...t. 10 /- Boston Scientific,...dule of the Company,s major,events and press annou...,s,(CRF) twentieth annual Transcatheter Cardiovasc...h runs from October 12 to 17 in Washington, D.C., ... of safety and,efficacy data on its TAXUS(R) Expre...
(Date:10/9/2008)... Results Expected in November 2008, BOTHELL, Wash...Inc.,(Amex: DDD ) announced today the completion ...its three pivotal trials to evaluate the safety an...release (ER) ibuprofen for,the over-the-counter (O...,results from this pivotal trial in November 2008....
(Date:10/8/2008)...meday Inform Treatments for Spinal Cord, Other Ner...SNewswire/ -- A protein that enables,nerve cells t...controlling,the developing nervous system. Researc...to form among nerve cells may provide a basis for ...es to their nervous system,including spinal cord ...
Breaking Medicine Technology:TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 3Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 4Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 6SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Miami Hospital Market Sees Shift in Ownership of Two Area Facilities 16345 1Miami Hospital Market Sees Shift in Ownership of Two Area Facilities 16345 2Management Consultancy Announces Inaugural Infinitive Championship Series 16343 1Management Consultancy Announces Inaugural Infinitive Championship Series 16343 2Stemline Therapeutics Raises 2412 5 Million 4492 1People With Diabetes May Have All Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels 1725 1People With Diabetes May Have All Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels 1725 2People With Diabetes May Have All Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels 1725 3
...Laboratories, Inc. Today,Announced the Top Line Re...c Stroke) Study with the Compound Desmoteplase , A...urt Stock,Exchange, Prime Standard: PA8) and its U...day announced topline results of,the DIAS-2 (Desmo...ompound Desmoteplase. The Phase III study was desi...
...ire-FirstCall/ - Research,collaborators with Oncol... deliver a poster presentation covering REOLYSIN(R...linical Oncology,(ASCO) Annual Meeting, to be held...esults of Oncolytics, U.K. Phase I systemic,admini...lts of a Phase I Study of,Wild-Type Oncolytic Reov...
Other Medicine Technology:Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 2Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 3Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 4Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference 2
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...rom the ban on smoking and they are already stocki... the ban. The Smoking ban, in public places, whic...rt from the public of Britain. Three quarter of th...ms are looking for an opening in areas where smoke...
...perm banks are at a premium among Afghan couples, ..., infertile Afghan couple do scout around for sper... it is perhaps the never-ending conflicts, sparked...ght have contributed to stress-related hormonal di...
...High Court judges to uphold her right to wear a ri...dependent, Lydia Playfoot, who has taken a vow of ...ex of discriminating against Christians after the ... ban on "purity rings". Lydia argued that she is ...
...ocusts ravaged Timor-Leste's harvest in 2007, cutt... cent and leaving one-fifth of the population in n...ay by the United Nations Food and Agriculture Orga...d Programme (WFP). To avert a major food crisis, ...
Other Medicine News:Health News:Pubs Propose to Sell Nicotine Gum Patches 2Health News:Afghan Couple Turn to Indian Sperm Banks for Help 2Health News:One Fifth of Timor Needs Food Assistance: UN Report 2
Microprocessor-based isolated electrosurgical generator, designed for all general surgical procedures. Unit includes the Valleylab adaptive REM system and Instant Response technology.
Lorgnette pinhole occluder
Long handle occluder - White
Double Ended Occluders
Medicine Products: